Table 2.
Comparison of characteristics between the non-PEU and PEU groups
| Characteristics | Non-PEU | PEU | P-value | |
|---|---|---|---|---|
| (n = 34) | (n = 27) | |||
| Age (year), median [IQR] | 47 [36–59] | 58 [41.50–67.50] | 0.155 | |
| Male / Female, n (%) | 20 (58.8) / 14 (41.2) | 20 (74.1) / 7 (25.9) | 0.281 | |
| Disease duration (year), median [IQR] | 9 [5–13] | 8 [5–15] | 0.925 | |
| Disease extent, n (%) | Extensive colitis | 17 (50.0) | 25 (92.6) | 0.001 |
| Left-sided colitis | 10 (29.4) | 2 (7.4) | ||
| Proctitis | 7 (20.6) | 0 (0.0) | ||
| CAI (Rachmilewitz index), median [IQR] | 0 [0–0] | 0 [0–0] | 0.660 | |
| Medication at study, n (%) | Oral 5-ASA | 23 (67.6) | 19 (70.4) | 1 |
| Suppository Steroids | 0 (0.0) | 2 (7.4) | 0.192 | |
| Systemic steroids | 3 (8.8) | 4 (14.8) | 0.689 | |
| Immunomodulators | 8 (23.5) | 8 (29.6) | 0.770 | |
| Biologics | 13 (38.2) | 15 (55.6) | 0.205 | |
PEU Past extensive ulcer, IQR interquartile range, CAI clinical activity index, 5-ASA 5-aminosalicylic acid